Trial Profile
Reduced Intensity Conditioning Allogeneic Transplantation for CLL With Preemptive MDR Management (ICLL 03 RICAC-PMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Haematopoietic stem cell therapy (Primary) ; Antithymocyte globulin; Busulfan
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RICAC
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting, as per an abstract presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2015 Preliminary results (n=30) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 20 May 2013 New trial record